Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of AbbVie Inc. patents

Patents where

Current Assignee

Name

AbbVie Inc.

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11773106 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 11773106 was granted and assigned to AbbVie Inc. on October, 2023 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11773106	October 3, 2023
‌ US Patent 11780848 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof	Patent 11780848 was granted and assigned to AbbVie Inc. on October, 2023 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11780848	October 10, 2023
‌ US Patent 11767326 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 11767326 was granted and assigned to AbbVie Inc. on September, 2023 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11767326	September 26, 2023
‌ US Patent 11976077 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof	Patent 11976077 was granted and assigned to AbbVie Inc. on May, 2024 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11976077	May 7, 2024
‌ US Patent 11780847 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof	Patent 11780847 was granted and assigned to AbbVie Inc. on October, 2023 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11780847	October 10, 2023
‌ US Patent 11787815 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 11787815 was granted and assigned to AbbVie Inc. on October, 2023 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11787815	October 17, 2023
‌ US Patent 11773105 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 11773105 was granted and assigned to AbbVie Inc. on October, 2023 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11773105	October 3, 2023
‌ US Patent 11564922 Methods of treating crohn's disease and ulcerative colitis	Patent 11564922 was granted and assigned to AbbVie Inc. on January, 2023 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11564922	January 31, 2023
‌ US Patent 11535626 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof	Patent 11535626 was granted and assigned to AbbVie Inc. on December, 2022 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11535626	December 27, 2022
‌ US Patent 11661425 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 11661425 was granted and assigned to AbbVie Inc. on May, 2023 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11661425	May 30, 2023
‌ US Patent 11524964 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 11524964 was granted and assigned to AbbVie Inc. on December, 2022 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11524964	December 13, 2022
‌ US Patent 12110297 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 12110297 was granted and assigned to AbbVie Inc. on October, 2024 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	12110297	October 8, 2024
‌ US Patent 11512092 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 11512092 was granted and assigned to AbbVie Inc. on November, 2022 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11512092	November 29, 2022
‌ US Patent 11680069 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 11680069 was granted and assigned to AbbVie Inc. on June, 2023 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11680069	June 20, 2023
‌ US Patent 10981924 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 10981924 was granted and assigned to AbbVie Inc. on April, 2021 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	10981924	April 20, 2021
‌ US Patent 11535625 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 11535625 was granted and assigned to AbbVie Inc. on December, 2022 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11535625	December 27, 2022
‌ US Patent 10344036 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof	Patent 10344036 was granted and assigned to AbbVie Inc. on July, 2019 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	10344036	July 9, 2019
‌ US Patent 10202393 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 10202393 was granted and assigned to AbbVie Inc. on February, 2019 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	10202393	February 12, 2019
‌ US Patent 10202394 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 10202394 was granted and assigned to AbbVie Inc. on February, 2019 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	10202394	February 12, 2019
‌ US Patent 9408973 Automatic injection device	Patent 9408973 was granted and assigned to AbbVie Inc. on August, 2016 by the United States Patent and Trademark Office.		AbbVie Inc.	United States Patent and Trademark Office	9408973	August 9, 2016
‌ US Patent 11358773 Medication packaging and dispensing system	Patent 11358773 was granted and assigned to AbbVie Inc. on June, 2022 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11358773	June 14, 2022
‌ US Patent 11535624 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 11535624 was granted and assigned to AbbVie Inc. on December, 2022 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11535624	December 27, 2022
‌ US Patent 11186584 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 11186584 was granted and assigned to AbbVie Inc. on November, 2021 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11186584	November 30, 2021
‌ US Patent 10995095 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof	Patent 10995095 was granted and assigned to AbbVie Inc. on May, 2021 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	10995095	May 4, 2021
‌ US Patent 11198697 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 11198697 was granted and assigned to AbbVie Inc. on December, 2021 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11198697	December 14, 2021

...

Results per page:

670 results

0 selected

670 results

0 selected